CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Eyal Rubin

Former CFO, Protalix BioTherapeutics

Search every verified Eyal Rubin interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Eyal Rubin, former CFO of Protalix Biotherapeutics, discussed the company's financial and operational challenges during an August ​2023 appearance on the podcast "The Business of Biotech." He described efforts to stabilize the company, including engaging with investors and addressing a share price that had declined significantly from a peak valuation of approximately $1.2 billion following the approval of its drug Elelyso. Rubin also commented on the company's investor base, stating that Protalix sought to attract more institutional investors while acknowledging the support of long-term retail shareholders. Rubin reflected on his broader experience in biotech finance, including prior roles at Teva Pharmaceuticals and Protalix, and described a management approach that emphasized transparency and open discussion of challenges. He credited former Protalix CEO George (likely referring to George Shaked) with fostering a unique corporate culture that helped navigate difficult periods, and noted that the company had not given up despite ongoing difficulties.

Recent appearances

  • Fiscal Turnarounds With Protalix's Eyal Rubin

    September 04, 2023 · 📺 Life Science Connect

    Within about five minutes of conversation with Protalix CFO Eyal Rubin, I learned that he doesn’t bite his tongue about the rigors of biotech business and finance management, which is precisely why I’m eager to talk with him on today’s episode of the podcast. From commercialization deals with big pharma to being about $50 million underwater to swatting away the day trading armchair quarterbacks on Stocktwits, Rubin’s seen a few things and he’s developed more than a few opinions.  On this episode of the Business of Biotech, you'll get a front-row seat to a discussion with a biotech CFO who kno…

    Watch on YouTube ↗

  • Protalix Fireside Chat. CEO Dror Bashan, CFO Eyal Rubin and Zacks Analyst John Vandermosten

    July 02, 2021 · 📺 Unboxing Biotech

    Protalix Biotherapeutics, Inc. Reports 1Q:21 Results & Next Steps Following CRL https://s27.q4cdn.com/906368049/files... Target Action Date Four Weeks Away https://s27.q4cdn.com/906368049/files... $40 Million Raise; SarcoMed Licensing https://s27.q4cdn.com/906368049/files... FDA Approval To Start New Chapter https://s27.q4cdn.com/906368049/files...

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →